|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Cengent Therapeutics Signs Genes-To-Leads Drug Discovery Contract With Dynamis Therapeutics
10/19/2005 5:12:11 PM
Cengent Therapeutics, a structure-guided drug discovery company, announced today the signing of a Genes-To-Leads(R) drug discovery contract with Dynamis Therapeutics, Inc., a Pennsylvania based biotechnology company. Under the agreement, Cengent will apply its proprietary platform lead identification technology, Genes To Leads(R), to screen for drug candidates against diabetic related kidney and heart disease, blindness and neuropathy. The proprietary drug target of Dynamis Therapeutics, Inc. is an enzyme that causes the formation of 3-deoxyglucosone. 3-deoxyglucosone is an adversely reactive molecule that causes the formation of free radicals and AGEs, Diabetics suffering from blindness and kidney disease have elevated levels regardless of glucose levels or caloric intake. The agreement includes up-front and milestone payments.
|
|
|
|
|
|
|
|
|
|
|